AstraZeneca Files Lawsuit Against LEK Pharmaceutical and Chemical Company d.d.Business Editors LONDON--(BUSINESS WIRE)--June 20, 2000 AstraZeneca today filed a lawsuit in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of against LEK Pharmaceutical and Chemical Company d.d. (LEK) and its US subsidiary, LEK USA, Inc. for patent infringement. The lawsuit is the result of an Abbreviated New Drug Application abbreviated new drug application Pharmacology An application made in the US by a pharmaceutical company requesting authority to market a 'new' drug for which both its therapeutic indications and formulation were previously approved by the FDA in another similar (ANDA ANDA abbr. abbreviated new drug application ) filed by LEK with the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) concerning its intent to market a generic omeprazole product in the US. The antisecretory antisecretory /an·ti·se·cre·to·ry/ (-se-kre´tah-re) 1. secretoinhibitory; inhibiting or diminishing secretion. 2. an agent that so acts, as certain drugs that inhibit or diminish gastric secretions. drug omeprazole is marketed in the US by AstraZeneca, L.P. under the brand name Prilosecr and is marketed internationally by AstraZeneca as Losecr. The basis for AstraZeneca's complaint is that the action by LEK infringes several patents relating to Prilosecr, which provide protection to the year 2014. These patents include coverage for formulations and for methods of using Prilosecr. The substance patent, which expires in 2001, has not been challenged by LEK. AstraZeneca intends to fully enforce its patent rights and is steadfast in its belief that all of the patents are valid. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion